TW202334222A - 結合gprc5d的抗體及其用途 - Google Patents

結合gprc5d的抗體及其用途 Download PDF

Info

Publication number
TW202334222A
TW202334222A TW111142114A TW111142114A TW202334222A TW 202334222 A TW202334222 A TW 202334222A TW 111142114 A TW111142114 A TW 111142114A TW 111142114 A TW111142114 A TW 111142114A TW 202334222 A TW202334222 A TW 202334222A
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
variable region
acid sequence
sequence shown
Prior art date
Application number
TW111142114A
Other languages
English (en)
Chinese (zh)
Inventor
陸臻楨
王玉潔
彭雙莉
張正平
Original Assignee
大陸商正大天晴藥業集團股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商正大天晴藥業集團股份有限公司 filed Critical 大陸商正大天晴藥業集團股份有限公司
Publication of TW202334222A publication Critical patent/TW202334222A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111142114A 2021-11-05 2022-11-04 結合gprc5d的抗體及其用途 TW202334222A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111305149 2021-11-05
CN202111305149.7 2021-11-05

Publications (1)

Publication Number Publication Date
TW202334222A true TW202334222A (zh) 2023-09-01

Family

ID=86240662

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142114A TW202334222A (zh) 2021-11-05 2022-11-04 結合gprc5d的抗體及其用途

Country Status (6)

Country Link
EP (1) EP4428153A4 (https=)
JP (1) JP2024540148A (https=)
KR (1) KR20240099351A (https=)
CN (1) CN118159565A (https=)
TW (1) TW202334222A (https=)
WO (1) WO2023078382A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116925229B (zh) * 2023-09-19 2023-12-15 南京驯鹿生物技术股份有限公司 一种靶向gprc5d的抗体及其应用
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
US12545726B1 (en) 2025-07-22 2026-02-10 Integral Molecular, Inc. Compositions and methods related to GPRC5D binding agents and variants thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017011932A8 (pt) * 2014-12-05 2022-11-08 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
SG11201907321TA (en) * 2017-02-07 2019-09-27 Daiichi Sankyo Co Ltd Anti-gprc5d antibody and molecule comprising the antibody
TWI829667B (zh) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
BR112021013824A2 (pt) * 2019-01-18 2021-12-14 Janssen Biotech Inc Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos
CA3248329A1 (en) * 2019-07-31 2025-11-29 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d

Also Published As

Publication number Publication date
WO2023078382A1 (zh) 2023-05-11
EP4428153A4 (en) 2026-02-11
KR20240099351A (ko) 2024-06-28
EP4428153A1 (en) 2024-09-11
JP2024540148A (ja) 2024-10-31
CN118159565A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
JP7317272B2 (ja) Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
EP4428153A1 (en) Antibody binding to gprc5d and use thereof
CN112703013B (zh) Cd3抗原结合片段及其应用
CN112969716B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
TW201922792A (zh) Cd96 抗體、其抗原結合片段及醫藥用途
WO2019137397A1 (zh) Pd-l1抗体、其抗原结合片段及医药用途
US20250145705A1 (en) Gprc5d antibody and application thereof
TW202128765A (zh) 一種雙特異性抗體
CN113840836B (zh) 抗结缔组织生长因子抗体及其应用
TW202448948A (zh) 靶向g蛋白偶聯受體的雙特異性抗體
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US20250154268A1 (en) Antibody targeting cd25, and preparation method therefor and use thereof
WO2023178645A1 (zh) 靶向cd3的抗体及其应用
CN118556082A (zh) p95HER2抗体及其应用
WO2024131846A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
AU2024331841A1 (en) Antibody targeting receptor tyrosine kinase-like orphan receptor 1 and use thereof
JP2026506623A (ja) 抗ｃｄｈ６抗体及びその使用
WO2024046245A1 (zh) 抗pvrig抗体及其应用
CN120988130A (zh) Siglec-15特异性单克隆抗体的制备及抗肿瘤效应
JP2026513553A (ja) 抗ｂｄｃａ２抗体
WO2024255683A1 (zh) 抗bdca2抗体
CN120842400A (zh) 泌乳素受体抗体及其用途
CN118894943A (zh) 靶向密蛋白的双特异性抗体
HK40064840A (en) Anti-connective tissue growth factor antibody and application thereof
HK40064840B (en) Anti-connective tissue growth factor antibody and application thereof